Page last updated: 2024-11-10

clopidogrel carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clopidogrel carboxylic acid: InChIKey: DCASRSISIKYPDD-UHFFFAOYSA-N [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clopidogrel carboxylic acid : A thienopyridine that is 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-ylacetic acid substituted by a 2-chlorophenyl group at position 2. It is a metabolite of the drug clopidogrel. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4129546
CHEMBL ID3113411
CHEBI ID83504
SCHEMBL ID364610
SCHEMBL ID13403893
MeSH IDM0521120

Synonyms (26)

Synonym
2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetic acid
FT-0665124
FT-0665125
FT-0665126
clopidogrel carboxylic acid
CHEMBL3113411
chebi:83504 ,
(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetic acid
(2-chlorophenyl)-(6,7-dihydro-4h thieno[3,2-c]pyridine-5-yl)-acetic acid
(+/-)-alpha-(2-chlorophenyl)-6,7-dihydro-4h-thieno[3,2-c]pyridine-5-acetic acid
DCASRSISIKYPDD-UHFFFAOYSA-N
(+/-)-(2-chlorophenyl)-(6,7-dihydro-4h-thieno[3,2-c]pyrid-5-yl)acetic acid
SCHEMBL364610
SCHEMBL13403893
2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetic acid
STL483386
AKOS030241522
Q27156885
90055-55-3
rac-clopidogrel carboxylic acid
clopidogrelcarboxylic acid
thieno[3,2-c]pyridine-5(4h)-acetic acid,a-(2-chlorophenyl)-6,7-dihydro-
DTXSID301144644
2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetic acid? (clopidogrel impurity pound(c)
CS-0165231
PD045007

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In conclusion, both non-metabolized clopidogrel and ticlopidine as well as metabolites of these compounds are toxic towards myeloid progenitor cells."( Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites.
Brecht, K; Donzelli, M; Krähenbühl, S; Maseneni, S; Taegtmeyer, AB, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" The therapeutic usefulness of clopidogrel has been limited by documented inter-individual heterogeneity in platelet inhibition, which may be attributable to known clopidogrel pharmacokinetic variability."( Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
Al-Zumyli, R; Arafat, T; Bulatova, NR; Yousef, AM, 2008
)
0.35
" Clopidogrel carboxylate plasma levels were measured and non-compartmental analysis was used to determine peak plasma concentration (C(max)), time to peak plasma concentration (T(max)), elimination half-life (t(1/2e)), and area under the curve (AUC(0-->infinity))."( Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
Al-Zumyli, R; Arafat, T; Bulatova, NR; Yousef, AM, 2008
)
0.35
" Additionally, the in vivo pharmacokinetic characterization of the chosen compounds was not hampered by the reduction of calibration standards (from n = 8 to n = 3)."( Influence of number of calibration standards within a defined range on pharmacokinetic disposition-case studies with omeprazole and clopidogrel carboxylic acid.
D'Souza, HJ; Kristjansson, F; Kumar, A; Pai, B; Shekar, R; Srinivas, NR, 2010
)
0.56
" The present first-in-human study assessed the pharmacokinetic and pharmacodynamic effects of PM103 and its safety in 144 healthy human subjects."( Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.
Adams, MP; Cooper, WD; Cushing, DJ; Kowey, PR; Machatha, S; Mosher, GL; Souney, PF; Zhang, B, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" PM103 is an intravenous formulation of clopidogrel being developed as an alternative to oral clopidogrel to provide for dosing flexibility in the emergent clinical setting."( Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.
Adams, MP; Cooper, WD; Cushing, DJ; Kowey, PR; Machatha, S; Mosher, GL; Souney, PF; Zhang, B, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
thienopyridineAny organic heterobicyclic compound whose skeleton results from the formal ortho-fusion of any bond of a pyridine with any bond of a thiophene.
monocarboxylic acidAn oxoacid containing a single carboxy group.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1068712Displacement of UDP-[14C]GlcNAc from TarO (unknown origin) after 2.5 hrs by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
AID1068713Ratio of MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 in presence of targocil to MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 by checkerboard broth microdilution assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
AID1068714Ratio of MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 in presence of cefuroxime to MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 by checkerboard broth microdilution assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's14 (77.78)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.50 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.11%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]